| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. | Chief Medical Officer | Stock Options (Right to buy) | 60K | $184K | $3.06 | Sep 11, 2023 | Direct |
| Reneo Pharmaceuticals, Inc. | Chief Medical Officer | Employee Stock Option (right to buy) | 131K | Oct 4, 2024 | Direct | ||
| INFINITY PHARMACEUTICALS, INC. | Director | Stock Option(right to buy) | 45K | Jun 16, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| OKUR | OnKure Therapeutics, Inc. | Oct 4, 2024 | 2 | $0 | 4 | Oct 8, 2024 | Chief Medical Officer |
| OKUR | OnKure Therapeutics, Inc. | Oct 4, 2024 | 0 | $0 | 3 | Oct 8, 2024 | Chief Medical Officer |
| FHTX | Foghorn Therapeutics Inc. | Sep 11, 2023 | 0 | $0 | 4 | Sep 13, 2023 | Chief Medical Officer |
| FHTX | Foghorn Therapeutics Inc. | Aug 16, 2023 | 3 | -$1.41M | 4 | Aug 18, 2023 | Chief Medical Officer |
| FHTX | Foghorn Therapeutics Inc. | Jan 26, 2023 | 1 | $0 | 4 | Jan 30, 2023 | Chief Medical Officer |
| INFI | INFINITY PHARMACEUTICALS, INC. | Jun 16, 2022 | 1 | $0 | 4 | Jun 16, 2022 | Director |
| FHTX | Foghorn Therapeutics Inc. | Jan 26, 2022 | 1 | $0 | 4 | Jan 28, 2022 | Chief Medical Officer |
| INFI | INFINITY PHARMACEUTICALS, INC. | Jun 10, 2021 | 1 | $0 | 4 | Jun 11, 2021 | Director |